Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of MEDI3506 in diabetic kidney disease
jRCT2080225044Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing MEDI3506 with Placebo (2 arms). Started Jan 2020; status: completed.
02
Drugs
tozorakimab
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080225044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225044.